A Comparison of Contrast Enhanced Ultrasound (CEUS) and Contrast Enhanced Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) for Characterization of Focal Liver Masses

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Foothills Medical Centre
Vancouver General Hospital
London Health Sciences Centre
Centre Hospitalier de l'Université de Montréal
Information provided by (Responsible Party):
Stephanie R Wilson, MD, Foothills Medical Centre
ClinicalTrials.gov Identifier:
First received: January 23, 2009
Last updated: October 7, 2014
Last verified: October 2014

This comparison study is performed to show equivalence of CEUS with CECT or CEMR to diagnose noninvasively focal liver masses. This is a multi-center prospective cohort study of 250 subjects, which will be performed at four institutions in Canada. Subjects with a focal liver mass, measuring at least 2.5 centimeters in maximal diameter, will undergo a conventional baseline sonogram followed by a contrast enhanced ultrasound (CEUS). CEUS will be performed on standard ultrasound scanners with contrast specific imaging capability. The contrast agent used is Definity( Lantheus Medical Imaging, Billerica,MA) All subjects will have either a dedicated hepatic contrast enhanced CT or MR scan within 60 days of the CEUS as per the standard of care in the institution. Anonymized image files from all imaging will be shown independently to two readers, blinded to all clinical and demographic data, who will predict malignancy and diagnosis.

Liver Tumors

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Characterization of Liver Masses With Contrast Enhanced Ultrasound (CEUS): A Comparison With Standard Institutional Contrast Enhanced CT (CECT) or MR Scan (CEMRI)

Resource links provided by NLM:

Further study details as provided by Foothills Medical Centre:

Primary Outcome Measures:
  • Malignancy of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI. [ Time Frame: 6-9 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Diagnosis of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI. [ Time Frame: 6-9 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 250
Study Start Date: January 2009
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
liver mass
The group will comprise any patients with an unknown liver mass at the time of diagnostic imaging.


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Any patient with an unknown liver mass


Inclusion Criteria:

  • An incidental liver mass amenable to US evaluation
  • Undiagnosed liver mass
  • Mass threshold size is 2.5 cm
  • Source of subjects:

    • Liver mass found on conventional institutional US
    • Liver mass detected on CT and MRI that remain uncategorized
    • Referral of patient with a liver mass following detection in outside institution.
  • Confirmatory CT or MRI performed within 60 days of initial scan according to the institutional protocols

Exclusion Criteria:

  • Any known pre existing mass
  • Pregnancy
  • Severe or unstable cardiac disease, including angina, congestive heart failure, or arrhythmias
  • Severe COPD
  • Pulmonary hypertension
  • Bidirectional shunts
  • Transient right to left shunts
  • Known hypersensitivity to Definity or any of its components
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00828607

Contact: Stephanie R Wilson, MD 403 944 2680 stephanie.wilson@albertahealthservices.ca
Contact: Sharron Martel 403 944 2116 sharron.martel@albertahealthservices.ca

Canada, British Columbia
Vancouver General Hospital Recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Contact: Alison Harris, MD    604 875 4340    Alison.Harris@vch.ca   
Sub-Investigator: Alison Harris, MD         
Canada, Ontario
London Health Sciences Centre, University Hospital Recruiting
London, Ontario, Canada, N6A 5A5
Contact: Cesare Romagnoli, MD    519-685-8500 ext 32333    Cesare.Romagnoli@LHSC.ON.CA   
Contact: Lisa Hagerty    519-685-8500 ext 32333    lisa.hagerty@lhsc.on.ca   
Sub-Investigator: Cesare Romagnoli, MD         
Sunnybrook Medical centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Laurent Milot, MD    416 180 6100 ext 7418    laurentt.milot@sunnybrook.ca   
Sub-Investigator: Laurent Milot, MD         
Canada, Quebec
Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc Recruiting
Montréal, Quebec, Canada, H2X 3J4
Contact: Jessica Murphy-Lavallee, MD    (514) 890-8350 ext 3-5616    j_murphylavallee@hotmail.com   
Contact: Christelle Poupard    514 890-8350 ext 3-5616      
Sub-Investigator: Jessica Murphy-Lavallee, MD         
Sponsors and Collaborators
Foothills Medical Centre
Vancouver General Hospital
London Health Sciences Centre
Centre Hospitalier de l'Université de Montréal
Principal Investigator: Stephanie R Wilson, MD Foothills Medical Centre
  More Information

No publications provided

Responsible Party: Stephanie R Wilson, MD, Clinical Professor University of Calgary, Foothills Medical Centre
ClinicalTrials.gov Identifier: NCT00828607     History of Changes
Other Study ID Numbers: (Ethics ID: 21295)
Study First Received: January 23, 2009
Last Updated: October 7, 2014
Health Authority: Canada: Health Canada

Keywords provided by Foothills Medical Centre:
Contrast Enhanced Ultrasound (CEUS)
Liver tumors
Hepatocellular carcinoma
Focal Nodular Hyperplasia
Hepatic metastases

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms by Site
Contrast Media
Diagnostic Uses of Chemicals
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2015